Literature DB >> 11164416

Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet.

D Sunnemark1, R A Harris, J Frostegård, A Orn.   

Abstract

In addition to established factors such as hyperlipidemia, smoking and hypertension, inflammation and infection have recently been implicated as major risk factors for atherosclerotic disease. Proatherogenic effects induced by infection may be related to both systemic inflammation and to direct effects on the vascular wall. We report here that a high fat diet combined with a protozoal infection with known tropism to the heart induced early atherosclerosis and intimal inflammatory infiltrates (CD4+, CD8+ cells and macrophages) in aortas of all (n = 7) CBA/J mice investigated. These mice are normally quite resistant to atherosclerotic development and in the control group (n = 7) receiving only a fatty diet, only one mouse presented a lesion. This lesion was completely devoid of infiltrating CD8+ cells. Parasite-infected mice receiving a normal diet exhibited vasculitis, but no signs of atherosclerosis and control mice receiving normal diet, as expected, exhibited neither signs of vasculitis nor atherosclerosis. Secretion of IL-6, TNF-alpha, and IFN-gamma were demonstrated in all atherosclerotic lesions and IL-6 appeared to be the dominant cytokine, both in the lesions themselves as well as in the intimal-medial junction. There were no traces of parasites present in the artery wall, indicating that atherosclerosis was induced via an indirect route. We conclude that a high fat diet in conjunction with infection and systemic (or localized) inflammation may have a strong proatherogenic effect. Finally, we suggest that CBA/J mice infected with T. cruzi parasites and given a fatty diet could serve as a useful experimental model in the continued analysis of factors contributing to the induction of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164416     DOI: 10.1016/s0021-9150(00)00406-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Infection with Toxoplasma gondii increases atherosclerotic lesion in ApoE-deficient mice.

Authors:  Luciane R Portugal; Luciana R Fernandes; Giovana C Cesar; Helton C Santiago; Dirce R Oliveira; Neide M Silva; Andrea A Silva; Joseli Lannes-Vieira; Rosa M E Arantes; Ricardo T Gazzinelli; Jacqueline I Alvarez-Leite
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders.

Authors:  Luisina I Onofrio; Alfredo R Arocena; Augusto F Paroli; María E Cabalén; Marta C Andrada; Roxana C Cano; Susana Gea
Journal:  PLoS Negl Trop Dis       Date:  2015-02-10

Review 3.  Trypanosoma cruzi infection and host lipid metabolism.

Authors:  Qianqian Miao; Momar Ndao
Journal:  Mediators Inflamm       Date:  2014-09-03       Impact factor: 4.711

4.  Chronic Trypanosoma cruzi infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity model.

Authors:  María E Cabalén; María F Cabral; Liliana M Sanmarco; Marta C Andrada; Luisina I Onofrio; Nicolás E Ponce; María P Aoki; Susana Gea; Roxana C Cano
Journal:  Oncotarget       Date:  2016-03-22

5.  Evidence for host genetic regulation of altered lipid metabolism in experimental toxoplasmosis supported with gene data mining results.

Authors:  Ivan Milovanović; Miloš Busarčević; Alexander Trbovich; Vladimir Ivović; Aleksandra Uzelac; Olgica Djurković-Djaković
Journal:  PLoS One       Date:  2017-05-01       Impact factor: 3.240

6.  Early Trypanosoma cruzi infection reprograms human epithelial cells.

Authors:  María Laura Chiribao; Gabriela Libisch; Adriana Parodi-Talice; Carlos Robello
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.